October 24, 2019
AVROBIO secures USFDA’s Orphan-Drug Designation for Gaucher Disease treatment, AVR‑RD‑02
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted…